Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Sales and Divestitures (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Gains from Sales and Divestitures data on record, last reported at $372218.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 4.23% year-over-year to $372218.0; the TTM value through Sep 2025 reached $372218.0, down 4.23%, while the annual FY2024 figure was $388816.0, 11.73% down from the prior year.
  • Gains from Sales and Divestitures reached $372218.0 in Q3 2025 per AMPH's latest filing, up from $367827.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $493718.0 in Q4 2021 and bottomed at $338280.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 5 years is $422272.5, with a median of $417007.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: decreased 21.39% in 2021, then increased 0.01% in 2022.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $493718.0 in 2021, then dropped by 3.17% to $478068.0 in 2022, then fell by 7.86% to $440484.0 in 2023, then dropped by 11.73% to $388816.0 in 2024, then fell by 4.27% to $372218.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $372218.0 in Q3 2025, $367827.0 in Q2 2025, and $338280.0 in Q1 2025.